Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 22, 2024

Osimertinib Plus Local Treatment for Brain Metastases vs Osimertinib Alone in Patients With EGFR-Mutant NSCLC

Lung Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

Lung Cancer
Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer
Lung Cancer 2024 Mar 22;[EPub Ahead of Print], T Tozuka, R Noro, H Mizutani, et al

Further Reading